Randomized Trial of Single Agent Paclitaxel Given Weekly Versus Every Three Weeks and with Peroral Versus Intravenous Steroid Premedication to Patients with Ovarian Cancer Previously Treated with Platinum

Personalized Cancer Treatment for Ovarian Cancer

“…Given that the platinum-sensitive recurrent ovarian cancers responses to 2 nd line chemotherapy in 47.2-61.7% (Bolis et al, 2001;Cantu et al, 2002;Parmar et al, 2003;Pfisterer et al, 2006) and platinum-refractory responses in only 6.1-25.7% (ten Bokkel et al, 1997;Gordon et al, 2001;Rosenberg et al, 2002;Berkenblit et al, 2004Cannistra et al 2007Mutch et al, 2007), this group of patients treated at Burzynski's Clinic should response in 6.1-25.7%, similar to platinum-refractory cases. Surprisingly, they responded in 42.42%.…”

“…Markedly lower OR of 6.1-25.7% was reported with single agent chemotherapies: [topotecan (ten Bokkel et al, 1997), pegylated liposomal doxorubicin (Gordon et al, 2001), weekly paclitaxel (Rosenberg et al, 2002), docetaxel (Berkenblit et al, 2004), gemcitabine (Mutch et al, 2007), and bevacizumab (Cannistra et al. 2007)] for platinum resistant diseases .…”

Treatment Outcomes of Paclitaxel for Refractory or Recurrent Epithelial Ovarian Cancer Patients in Thailand

“…Few studies reported only 4-8% of grade 3-4 neutropenia in their patients who had weekly paclitaxel (Markman et al, 2006;Linch et al, 2008). One randomized phase III trial by Rosenberg et al compared the toxicity of tri-weekly versus weekly paclitaxel in 208 patients (Rosenberg et al, 2002). Grade 3-4 neutropenia were lower in those who had the weekly regimen, 18% vs 45%.…”

“…Focusing on the role of paclitaxel given beyond a primary setting, the drug can be used in conjunction with carboplatin in platinum-sensitive patients (who may have or have not taxane) (Parmar et al, 2003) or it can be used in refractory or platinum-resistant patients who have not had paclitaxel as a primary treatment (taxane-naïve) (Rosenberg et al, 2002). The response rate of diseases to paclitaxel varied from 13-45% (Trimble et al, 1993;ten Bokkel Huinink et al, 1997;Cantu et al, 2002;Rosenberg et al, 2002;Buda et al, 2004;Markman et al, 2006).…”

“…The response rate of diseases to paclitaxel varied from 13-45% (Trimble et al, 1993;ten Bokkel Huinink et al, 1997;Cantu et al, 2002;Rosenberg et al, 2002;Buda et al, 2004;Markman et al, 2006). This wide range of response depends mainly on the sensitivity to previous therapy or the setting when the drug is used.…”